ReviewGenome research2015
The path to routine use of genomic biomarkers in the cancer clinic.
Review in Genome research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- The Prognostic Value of the Hedgehog Signaling Pathway in Ovarian Cancer.International journal of molecular sciences · 2025Article
- Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation.Scientific reports · 2025Article
- ssMutPA: single-sample mutation-based pathway analysis approach for cancer precision medicine.GigaScience · 2024Article
- Advances in transcriptomics and proteomics in differentiated thyroid cancer: An updated perspective (Review).Oncology letters · 2023Review
- ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers.Molecular systems biology · 2022Article
- Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis.EBioMedicine · 2022Article
- Identification of human gene research articles with wrongly identified nucleotide sequences.Life science alliance · 2022Article
- The clonal expression genes associated with poor prognosis of liver cancer.Frontiers in genetics · 2022Article
- Tracking Cancer Evolution through the Disease Course.Cancer discovery · 2021Review
- Mechanism-Centric Approaches for Biomarker Detection and Precision Therapeutics in Cancer.Frontiers in genetics · 2021Review
- BATCAVE: calling somatic mutations with a tumor- and site-specific prior.NAR genomics and bioinformatics · 2020Article
- Identification of the Mutational Landscape of Gynecological Malignancies.Journal of Cancer · 2020Article
- Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology.Nature reviews. Clinical oncology · 2019Review
- A clonal expression biomarker associates with lung cancer mortality.Nature medicine · 2019Article
- Cytogenetics and Cytogenomics Evaluation in Cancer.International journal of molecular sciences · 2019Review
- The Possibility of Systematic Research Fraud Targeting Under-Studied Human Genes: Causes, Consequences, and Potential Solutions.Biomarker insights · 2019Review
- Next Generation Sequencing in Clinical Oncology: Applications, Challenges and Promises: A Review Article.Iranian journal of public health · 2018Review
- Prediction of early breast cancer patient survival using ensembles of hypoxia signatures.PloS one · 2018Article
- Biomarkers of Duchenne muscular dystrophy: current findings.Degenerative neurological and neuromuscular disease · 2018Review
- Experimental design and quantitative analysis of microbial community multiomics.Genome biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
It has been almost 15 years since the first microarray-based studies creating multigene biomarkers to subtype and predict survival of cancer patients. This Perspective looks at why only a handful of genomic biomarkers have reached clinical application and what advances are needed over the next 15 years to grow this number. I discuss challenges in creating biomarkers and reproducing them at the genomic and computational levels, including the problem of spatio-genomic heterogeneity in an individual cancer. I then outline the challenges in translating newly discovered genome-wide or regional events, like trinucleotide mutation signatures, kataegis, and chromothripsis, into biomarkers, as well as the importance of incorporating prior biological knowledge. Lastly, I outline the practical problems of pharmaco-economics and adoption: Are new biomarkers viewed as economically rational by potential funders? And if they are, how can their results be communicated effectively to patients and their clinicians? Genomic-based diagnostics have immense potential for transforming the management of cancer. The next 15 years will see a surge of research into the topics here that, when combined with a stream of new targeted therapies being developed, will personalize the cancer clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.